Pfizer  logo
Pfizer PFE
$ 27.4 -0.36%
report update icon

Quarterly report 2026-Q3
added 11-03-2026

Pfizer Accounts Payables | PFE

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Pfizer

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
5.24 B 5.63 B 6.71 B 6.81 B 5.58 B 4.28 B 4.22 B 4.67 B 4.66 B 4.54 B 3.62 B 3.44 B 3.23 B 4.26 B 3.84 B 3.99 B 4.37 B 1.75 B - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
6.81 B 1.75 B 4.49 B

Quarterly Accounts Payables Pfizer

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2 2010-Q1 2009-Q4 2009-Q3 2009-Q2
4.07 B 4.58 B 4.51 B 5.24 B 5.02 B 5.17 B 5.24 B 5.63 B 5.31 B 5.11 B 5.59 B 6.71 B 5.34 B 6.08 B 6.12 B 6.81 B 6.27 B 6.21 B 5.51 B 5.58 B 4.7 B 4.33 B 4.06 B 4.28 B 4.14 B 3.87 B 3.97 B 3.89 B 3.94 B 4 B 4.16 B 4.67 B 4.3 B 4.2 B 3.88 B 4.66 B 3.48 B 3.44 B 3.39 B 4.54 B 3.48 B 3.26 B 3.12 B 3.62 B 3.29 B 2.93 B 2.72 B 3.21 B 2.97 B 2.99 B 2.55 B 3.23 B 2.29 B 1.98 B 3.28 B 2.92 B 2.97 B 3.16 B 3.09 B 3.68 B 3.76 B 3.7 B 3.75 B 3.99 B 3.21 B 3.08 B 3.03 B 4.37 B 2.48 B 2.6 B

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
6.81 B 1.98 B 4.1 B

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Prothena Corporation plc Prothena Corporation plc
PRTA
5.88 M $ 8.12 -3.33 % $ 437 M usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
2.91 M $ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
3.08 M $ 1.53 -8.68 % $ 555 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
3.51 M $ 7.73 -2.59 % $ 9.16 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
11.2 M $ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
2.09 M $ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
4.79 M $ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
5.34 M $ 121.72 -2.2 % $ 7.74 B usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
794 K $ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
42 M $ 15.62 -1.01 % $ 1.68 B usaUSA
Replimune Group Replimune Group
REPL
6.67 M $ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
2.58 M $ 6.62 -2.43 % $ 35.2 M usaUSA
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
451 K $ 1.95 -7.82 % $ 217 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
3.16 M $ 0.87 -33.79 % $ 45.7 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
7.1 M $ 553.08 -1.08 % $ 24.5 B usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
9.25 M $ 7.0 -2.1 % $ 609 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
4.02 M $ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
1.14 M $ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
1.96 M $ 2.2 -5.98 % $ 286 M usaUSA
Passage Bio Passage Bio
PASG
902 K $ 3.94 9.14 % $ 12.6 M usaUSA
Vaxcyte Vaxcyte
PCVX
70.9 M $ 55.37 -5.12 % $ 7.54 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
7.7 M $ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
12 M $ 4.21 1.08 % $ 1.32 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
12.4 M $ 6.94 -0.57 % $ 956 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
435 K $ 0.66 -7.55 % $ 3.95 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
24.6 M $ 300.01 -3.5 % $ 6.75 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
3.98 M $ 3.22 -1.08 % $ 248 M usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
4.15 M $ 5.57 -5.03 % $ 1.04 B usaUSA
Sana Biotechnology Sana Biotechnology
SANA
1.67 M $ 1.58 -9.2 % $ 400 M usaUSA
Outlook Therapeutics Outlook Therapeutics
OTLK
10.2 M $ 0.39 -2.79 % $ 13.6 M usaUSA
uniQure N.V. uniQure N.V.
QURE
5.17 M $ 19.32 -4.5 % $ 1.11 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
31 M $ 16.46 -4.41 % $ 1.62 B usaUSA
Rafael Holdings Rafael Holdings
RFL
7.01 M $ 0.94 5.89 % $ 48.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
21.4 M $ 7.16 -0.35 % $ 369 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
7.19 M $ 40.05 -2.78 % $ 720 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
1.39 M - -6.63 % $ 13.9 M usaUSA
I-Mab I-Mab
IMAB
427 M - - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
6.04 M $ 1.27 -8.27 % $ 49.8 M usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
462 M $ 514.68 -1.15 % $ 132 B usaUSA
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
2.95 M $ 13.67 -8.01 % $ 1.49 B usaUSA